Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
FLUDROCORTISONE ACETATE
Bristol-Myers Squibb Pharmaceuticals Ltd
0.1 Milligram
Tablets
1978-04-01
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Florinef 0.1 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains fludrocortisone acetate 0.1 mg. Also contains lactose, 59.59mg per tablet For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablet. Round, biconvex, white tablets, scored on one side and engraved on the other side with “SQUIBB” and “429”. The tablets can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For partial replacement therapy for primary adrenocortical insufficiency in Addison’s disease and for the treatment of salt-losing adrenogenital syndrome. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS Addison’s Disease A daily dosage range of 0.05 to 0.3 mg Florinef tablets orally. Supplementary parenteral administration of sodium- retaining hormones is not necessary. When an enhanced glucocorticoid effect is necessary, this should be achieved by concurrent administration of cortisone (6.25 to 25 mg) or hydrocortisone (5 to 20 mg) daily. Salt-losing Adrenogenital Syndrome The recommended oral dosage for treating salt-losing adrenogenital syndrome is one tablet (0.1 mg) to two tablets (0.2 mg) of Florinef daily. Restriction of sodium intake and supplementary potassium administration may be required. CHILDREN Daily dosage should be adjusted to the age and weight of the child and the severity of the condition. Caution should be used in the event of exposure to chickenpox, measles or other communicable diseases. (See 4.4 Special Warnings and Precautions for Use). ELDERLY No specific dosing recommendations (see Precautions). IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 18/04/2012_ _CRN Read the complete document